These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24142880)

  • 1. An essential role for decorin in bladder cancer invasiveness.
    El Behi M; Krumeich S; Lodillinsky C; Kamoun A; Tibaldi L; Sugano G; De Reynies A; Chapeaublanc E; Laplanche A; Lebret T; Allory Y; Radvanyi F; Lantz O; Eiján AM; Bernard-Pierrot I; Théry C
    EMBO Mol Med; 2013 Dec; 5(12):1835-51. PubMed ID: 24142880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
    Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
    J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer.
    Lodillinsky C; Rodriguez V; Vauthay L; Sandes E; Casabé A; Eiján AM
    J Urol; 2009 Aug; 182(2):749-55. PubMed ID: 19539312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.
    Loskog A; Ninalga C; Hedlund T; Alimohammadi M; Malmström PU; Tötterman TH
    Lab Anim; 2005 Oct; 39(4):384-93. PubMed ID: 16197705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling.
    Iozzo RV; Buraschi S; Genua M; Xu SQ; Solomides CC; Peiper SC; Gomella LG; Owens RC; Morrione A
    J Biol Chem; 2011 Oct; 286(40):34712-21. PubMed ID: 21840990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies.
    Sainio A; Nyman M; Lund R; Vuorikoski S; Boström P; Laato M; Boström PJ; Järveläinen H
    PLoS One; 2013; 8(10):e76190. PubMed ID: 24146840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
    Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
    Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.
    Varela JC; Imai M; Atkinson C; Ohta R; Rapisardo M; Tomlinson S
    Cancer Res; 2008 Aug; 68(16):6734-42. PubMed ID: 18701498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-I.
    Fabris VT; Lodillinsky C; Pampena MB; Belgorosky D; Lanari C; Eiján AM
    Cancer Genet; 2012 Apr; 205(4):168-76. PubMed ID: 22559978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
    Morillon YM; Su Z; Schlom J; Greiner JW
    J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of iNOS expression in tumor growth and maintenance of cancer stem cells in a bladder cancer model.
    Belgorosky D; Girouard J; Langle YV; Hamelin-Morrissete J; Marino L; Agüero EI; Malagrino H; Reyes-Moreno C; Eiján AM
    J Mol Med (Berl); 2020 Nov; 98(11):1615-1627. PubMed ID: 32955679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
    Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
    Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder.
    Appunni S; Anand V; Khandelwal M; Seth A; Mathur S; Sharma A
    Tumour Biol; 2017 May; 39(5):1010428317699112. PubMed ID: 28459201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice.
    Bi X; Pohl NM; Qian Z; Yang GR; Gou Y; Guzman G; Kajdacsy-Balla A; Iozzo RV; Yang W
    Carcinogenesis; 2012 Feb; 33(2):326-30. PubMed ID: 22159220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways.
    Girouard J; Belgorosky D; Hamelin-Morrissette J; Boulanger V; D'Orio E; Ramla D; Perron R; Charpentier L; Van Themsche C; Eiján AM; Bérubé G; Reyes-Moreno C
    Biochem Pharmacol; 2020 Jun; 176():113778. PubMed ID: 31877271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immunotherapy for metastatic bladder cancer using vaccine of human interleukin-2 surface-modified MB 49 cells.
    Zhang X; Shi X; Li J; Hu Z; Guo F; Huang X; Zhang Z; Sun P; Jing Y; Gao J; Tan W
    Urology; 2011 Sep; 78(3):722.e1-722.e6. PubMed ID: 21741685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dichotomy of decorin activity on the insulin-like growth factor-I system.
    Morrione A; Neill T; Iozzo RV
    FEBS J; 2013 May; 280(10):2138-49. PubMed ID: 23351020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of aberrantly expressed nuclear localized decorin attenuates tumour angiogenesis related mediators in oral cancer progression model in vitro.
    Dil N; Banerjee AG
    Head Neck Oncol; 2012 Jun; 4():11. PubMed ID: 22507529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.